The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.
 
Kazuya Takamochi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien/Medtronic; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kenji Suzuki
No Relationships to Disclose
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Seiji Niho
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Janssen; Kyorin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline (Inst); Kyowa Kirin International (Inst); Lilly Japan (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst); Teijin Pharma (Inst)
 
Satoshi Ishikura
Honoraria - Accuray Japan; AstraZeneca/Hong Kong
 
Shunsuke Oyamada
Honoraria - Chugai Pharma
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - 3H Clinical Trial; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED.; Eisai; EP Croit Co.; Incyte; Japan Tobacco Inc; Kowa; Ono Pharmaceutical; Otsuka; Seikagaku; Sonire Therapeutics
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Mebix; Takeda
Research Funding - 3H Clinical Trial (Inst); 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice (Inst); Eisai (Inst); Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Kyowa Kirin Co., Ltd.; Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Puravida Technologies (Inst); Senju Pharmaceutical (Inst); Welby (Inst)
 
Hirotoshi Horio
No Relationships to Disclose
 
Fumihiro Tanaka
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien/Medtronic; Intuitive Japan; Johnson & Johnson/Janssen; Kyowa Kirin International; Lilly Japan; MSD; Olympus Medical Systems; Ono Pharmaceutical; Pfizer; Stryker; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Satoshi Shiono
No Relationships to Disclose
 
Tomohiro Haruki
Honoraria - Intuitive Surgical
 
Norihito Okumura
No Relationships to Disclose
 
Ichiro Yoshino
Honoraria - Astellas Pharma; AstraZeneca/Hong Kong; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Intuitive Surgical; Johnson & Johnson/Janssen; Lilly O.; Medtronic; Shionogi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Intuitive Surgical; Johnson & Johnson/Janssen; Medicaroid; Medtronic
Research Funding - Daiichi Sankyo Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroyuki Ito
No Relationships to Disclose
 
Hidetaka Uramoto
Honoraria - AstraZeneca; Chugai Pharma
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); BMG Inc (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb KK (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)